Cover Image
市場調查報告書

Integrin Alpha 4:開發中產品分析

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364858
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
Integrin Alpha 4:開發中產品分析 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 74 Pages
簡介

本報告提供以Integrin Alpha 4為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Integrin Alpha 4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Antisense Therapeutics Limited
  • Atox Bio Ltd.
  • Biogen, Inc.
  • BioMAS Ltd.
  • 第一三共
  • EA Pharma Co Ltd
  • Protagonist Therapeutics Inc.
  • 武田藥品工業

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0911TDB

Summary:

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The latest report Integrin Alpha 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 3 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Infectious Disease, Oncology, Central Nervous System, Respiratory, Cardiovascular, Genetic Disorders, Ophthalmology and Toxicology which include indications Ulcerative Colitis, Asthma, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammatory Bowel Disease, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Celiac Disease, Chemotherapy Effects, Crohn's Disease (Regional Enteritis), Duchenne Muscular Dystrophy, Genital Warts (Condylomata Acuminata), Melanoma, Multiple Sclerosis, Paraneoplastic Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS) and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
    • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
    • Antisense Therapeutics Ltd
    • Biogen Inc
    • BioMAS Ltd
    • Daiichi Sankyo Company Ltd
    • EA Pharma Co Ltd
    • Immunwork Inc
    • Morphic Therapeutic Inc
    • Protagonist Therapeutics Inc
    • Takeda Pharmaceutical Company Ltd
    • Viriom Inc
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATL-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carotegrast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ET-3764 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • natalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTG-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TE-5232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vedolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy
      • Jun 26, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Application Submitted to the FDA
      • May 09, 2017: Provincial drug plans, including Ontario and BC, make ENTYVIO (vedolizumab) available to treat inflammatory bowel disease
      • May 08, 2017: New Real-World Analyses Support Effectiveness and Safety of Entyvio (vedolizumab) for Ulcerative Colitis and Crohns Disease
      • Apr 24, 2017: TYSABRI Data Demonstrates Improved Outcomes with Early MS Treatment at American Academy of Neurology in Boston
      • Apr 24, 2017: ATL1102 for Multiple Sclerosis - Phase IIb Investigational New Drug Submission
      • Apr 18, 2017: Biogen to Present Data on TYSABRI at AAN Congress
      • Feb 17, 2017: Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn;s and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease
      • Feb 17, 2017: Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidate PTG-100 at European Crohn's and Colitis Organization Congress
      • Jan 17, 2017: Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
      • Jan 05, 2017: Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100
      • Dec 09, 2016: GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naive Patients with Moderately to Severely Active Crohns Disease
      • Dec 08, 2016: Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference
      • Nov 24, 2016: Takeda's ENTYVIO (vedolizumab) receives positive reimburement recommendation from Common Drug Review for treatment of Crohns Disease
      • Nov 23, 2016: Takeda IBD Treatment ENTYVIO (vedolizumab) Receives Prestigious Prix Galien Canada Innovative Product Award
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Antisense Therapeutics Ltd, H2 2017
  • Pipeline by Biogen Inc, H2 2017
  • Pipeline by BioMAS Ltd, H2 2017
  • Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Pipeline by EA Pharma Co Ltd, H2 2017
  • Pipeline by Immunwork Inc, H2 2017
  • Pipeline by Morphic Therapeutic Inc, H2 2017
  • Pipeline by Protagonist Therapeutics Inc, H2 2017
  • Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Pipeline by Viriom Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top